Please login to the form below

Not currently logged in
Email:
Password:

BMS/Gilead HIV deal

Bristol-Myers Squibb and Gilead Sciences sign licensing agreement to develop and market a new fixed-dose combination HIV treatment

Bristol-Myers Squibb (BMS) and Gilead Sciences have signed a licensing agreement to develop and market a new fixed-dose combination HIV treatment.

The therapy contains BMS' protease inhibitor Reyataz (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

Gilead is currently studying atazanavir and cobicistat in phase II and III studies in HIV-1 treatment-naïve patients.

Under the terms of the agreement, BMS will pay Gilead an undisclosed royalty based on annual net sales of the product.

BMS will be responsible for the formulation, manufacturing, development, registration, distribution, and commercialisation of the fixed-dose combination worldwide.

Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.

Dr Elliott Sigal, executive vice president, chief scientific officer and president, R&D, BMS, said: "A Reyataz and cobicistat fixed-dose combination has the potential not only to help simplify HIV therapy but also to address an unmet medical need in HIV for additional, innovative treatment options."

27th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics